Proteomic screening for malignant melanoma antigen and development of antibody-based medicine for metastasis.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25670508
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Dermatology
• Research Institution: National Institutes of Biomedical Innovation, Health and Nutrition
• Principal Investigator: NAKA TETSUJI 国立研究開発法人医薬基盤・健康・栄養研究所, 免疫シグナルプロジェクト, シニアプロジェクトリーダー (30303936)
• Co-Investigator(Renkei-kenkyūsha): FUJIMOTO MINORU 国立研究開発法人医薬基盤・健康・栄養研究所, 医薬基盤研究所 免疫シグナルプロジェクト, 主任研究員 (00379190) ; SERADA SATOSHI 国立研究開発法人医薬基盤・健康・栄養研究所, 医薬基盤研究所 免疫シグナルプロジェクト, 研究員 (50463302)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 癌 / プロテオーム / タンパク質 / 抗体

Outline of Final Research Achievements

By quantitative proteomic approach, cell surface membrane proteins were screened by comparing normal human melanocytes and malignant melanoma cell lines. Elevated expression levels of the melanoma candidate antigen,Lipolysis-stimulated lipoprotein receptor (LSR), was confirmed by FACS analysis against cell lines compared to normal melanocytes. By immunohistochemical staining analysis, increased expression levels of the melanoma candidate antigen was also confirmed using malignant melanoma tissue sections. We developed 6 clones of novel chicken/mouse chimeric monoclonal antibody targeting this antigen. Several clones showed direct tumor growth inhibition in vitro. The detailed mechanisms of anti-tumor effects were investigated in vitro and in vivo.

Free Research Field

腫瘍免疫学